SURVIVAL OUTCOMES OF RITUXIMAB-BASED CHEMOTHERAPY IN HIGH-RISK B-CELL NON- HODGKIN LYMPHOMA IN PAKISTAN: EXPERIENCE FROM A LOW- AND MIDDLE-INCOME COUNTRY (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 176; Pres time: Sep 17, 2026; Location: Exhibition Area; "Rituximab-based immune-ochemotherapy improves survival in children with high-risk mature B-cell NHL in lower-middle-income countries. However, treatment-related infectious mortality remains a significant challenge, emphasizing the need for stronger supportive care and better infection-control measures in LMIC."
B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Lymphoma • Mucositis • Neutropenia • Non-Hodgkin's Lymphoma • Pneumonia • Respiratory Diseases • Septic Shock
|
|
Najma Shaheen1; Aqeela Rashid1; Irfana Sindhu1; Niaz Ali2
|